CML, Chronic Phase; TKI
Conditions
Brief summary
The ultimate goal of CML treatment is to improve survival, including overall survival (OS), progression-free survival (PFS), event-free survival (EFS), and treatment-free remission (TFR). TFR is a new therapeutic goal for chronic myeloid leukemia in chronic phase (CML-CP). In ENESTnd and DASISION trials, both nilotinib and dasatinib achieved DMR more effectively than imatinib. In the guidelines for diagnosis and treatment of chronic myeloid leukemia in China (2020 edition), flumatinib has been recommended as an appropriate first-line treatment for newly diagnosed chronic phase chronic myeloid leukemia (CML-CP) patients. There is no doubt that the second-generation TKIs show great advantages in deep molecular response, which further increases the possibility of achieving treatment-free remission. However, there is no direct comparative study to determine which TKI is better for de novo CML-CP. Thus, we conducted a multi-center, open-lable and real world study to compare the efficacy and safety between flumatinib and nilotinib.
Interventions
DRUGFlumatinib Mesylate
Flumatinib mesylate tablets 600mg qd
DRUGNilotinib Pill
Nilotinib Capsules 300mg bid
Sponsors
The First Affiliated Hospital of Soochow University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patients ≥18 years of age; 2. CML-CP patients diagnosed with CML within half a year；Patients who have been using second-generation TKI nilotinib or flumatinib for first-line treatment in clinical practice, but the history of continuous treatment does not exceed 3 months；3.patients are allowed to receive hydroxyurea treatment before first-line treatment with nilotinib or flumartinib; patients treated with interferon for no more than 3 months and other TKIs for no more than 2 weeks; 4.Patients who must sign informed consent before screening
Exclusion criteria
1. T315I mutation ; Y253F/H, E255K/V, F359C/V/I mutations in the nilotinib group; 2. Entry into another therapeutic clinical trial; 3. Concomitant diseases that, according to the investigator's judgment, pose a serious risk to the patient's safety or completion of the study; 4. History of neurological or psychiatric disorders, including epilepsy or dementia; 5. Major surgery within 4 weeks prior to Day 1 of study; 6. Patients with another primary malignancy,unless the other primary malignancy is currently stable or does not need active intervention; 7. Women of reproductive age or men who are unable to use adequate methods of contraception, including women who are pregnant or breastfeeding; 8. ECOG≥3; 9. Patients who are unable to compliance with study or follow-up procedures;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major molecular response rate at 12 months | 12 months | Major molecular response is defined as ≤ 0.1% BCR-ABL/ABL% by international scale |
Countries
China
Contacts
Primary ContactSuning Chen
Outcome results
None listed